Bruker this week reported a 33 percent increase year over year in Q2 revenues with its Scientific Instruments division, which houses its mass spectrometry business, also growing 33 percent.

While CEO Frank Laukien noted during a call discussing the results that recent mass spec releases like the maXis 4G UHR-QTOF and the maXis Impact likely hadn't contributed to these revenues, he said "order uptake is strong" for the new instruments, and they are "getting very good traction, very good interest."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.